Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06441695 · ClinicalTrials.gov registry record · NA
Acute Effects of PLT Health Solutions zümXR Extended-Release Caffeine
A NA study, sponsored by Applied Science & Performance Institute.
- Completed
- Registry status
- NA
- Development phase
- 36
- Enrollment target
NCT06441695 is a NA study that has completed, run by Applied Science & Performance Institute. The registered enrollment target is 36 participants.
The verdict
NCT06441695, a NA study, has completed, sponsored by Applied Science & Performance Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 36 participants
- Enrollment target
Study Summary
This will be a (2 visit) double-blind, randomized, crossover design clinical study to assess the potential benefits of ER-CAFF versus IR-CAFF by assessing its impact on side effect profiles, mood states, alertness, and cognitive abilities following ingestion after a suboptimal night of sleep. This study will enroll 30 healthy men and women who will be recruited by word of mouth, email contact, and direct contact from the greater Tampa Bay Area. To account for potential dropouts, we aim to enroll approximately 20% over the desired sample size (total of 36 participants). The anticipated study period will last approximately 2 weeks. After initial pre-screening, participants will report to the laboratory on two separate occasions after an overnight fast (10 hours minimum). Participants will be required to have a night of partial sleep deprivation the night before (\<5 hours sleep), which will be confirmed by self reported sleep logs and objective multisensor (triaxial accelerometry and cardiac data) wearable devices to accurately measure sleep deficit data. Upon arrival, participants will undergo baseline (BL) testing and then ingest a bolus of one study product with 4-8 ounces of water: 400 mg zümXR extended-release caffeine (ER-CAFF), or 400 mg of immediate-release caffeine anhydrous (IR-CAFF) (2 group, crossover design). Thereafter, participants will undergo subsequent testing sessions at 45, 60, 90, 135, 240, 300, 360, and 420 minutes post-supplementation. After the 4-hour (240 min) measurements, a caffeine-free food bar will be provided. This same food bar will also be offered to participants following the final 7-hour (420 min) measurements. The precise measures and timepoints for the measures are further defined below. There will be a one-week minimum washout period between treatments in the crossover design.
Interventions
- DIETARY_SUPPLEMENT xumXR extended release caffeine
- DIETARY_SUPPLEMENT immediate release caffeine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2024-06-13 |
| Est. Completion | 2024-10-25 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06441695
The ClinicalTrials.gov registry entry for NCT06441695 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Applied Science & Performance Institute, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which xumXR extended release caffeine is the first listed.
NCT06441695 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06441695 about?
NCT06441695 is a clinical study titled "Acute Effects of PLT Health Solutions zümXR Extended-Release Caffeine". This will be a (2 visit) double-blind, randomized, crossover design clinical study to assess the potential benefits of ER-CAFF versus IR-CAFF by assessing its impact on side effect profiles, mood states, alertness, and cognitive abilities following ingestion after a suboptimal night of sleep. This s...
What is the current status of trial NCT06441695?
This trial is currently completed. It is a NA study. The enrollment target is 36 participants. The study started on 2024-06-13. Estimated completion is 2024-10-25.
What interventions are being tested in trial NCT06441695?
The interventions under investigation include: xumXR extended release caffeine (DIETARY_SUPPLEMENT), immediate release caffeine (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06441695?
This trial is sponsored by Applied Science & Performance Institute, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.